¹⁷⁷Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

COMMENTED

Nuclear Medicine

[¹⁷⁷Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

Lancet Oncol

Emmett L, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, Weickhardt A, Lee ST, Ng S, Francis RJ, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Gedye C, Rutherford NK, Sandhu S, Kumar AR, Pook D, Ramdave S, Nadebaum DP, Voskoboynik M, Redfern AD, Macdonald W, Krieger L, Schembri G, Chua W, Lin P, Horvath L, Bastick P, Butler P, Zhang AY, Yip S, Thomas H, Langford A, Hofman MS, McJannett M, Martin AJ, Stockler MR, Davis ID, ENZA-p Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group

doi: 10.1016/S1470-2045(24)00135-9

COMMENTED

Genitourinary CancerNuclear Medicine

Overall survival with [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Lancet Oncol

Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, Stockler MR, Williams SG, Martin AJ, Davis ID, TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group

doi: 10.1016/S1470-2045(23)00529-6

Genitourinary Cancer

Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [(177)Lu]Lu-PSMA-617 in the Phase 3 VISION Trial

Eur Urol

Armstrong AJ, Sartor O, de Bono J, Chi K, Fizazi K, Krause BJ, Herrmann K, Rahbar K, Tagawa ST, Saad F, Beer TM, Wu J, Mirante O, Morris MJ

doi: 10.1016/j.eururo.2024.08.021

COMMENTED

Genitourinary CancerNuclear Medicine

Investigating Combination Therapy: The Role of Lutetium-177 PSMA-617 Radioligand Therapy and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer

★ 1 Recommended and commented by Prof. Dr Ken Herrmann, Faculty Member

J Clin Med

Kınıkoğlu O, Öven BB, Çelik S, Alan Selçuk N, Beydağı G, Akçay K, Kabasakal L

doi: 10.3390/jcm13164585

COMMENTED

Genitourinary CancerNuclear Medicine

Sequential [¹⁷⁷Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study

★ 3 Recommended and commented by Prof. Dr Ken Herrmann, Faculty Member

Lancet Oncol

Azad AA, Bressel M, Tan H, Voskoboynik M, Suder A, Weickhardt AJ, Guminski A, Francis RJ, Saghebi J, Dhiantravan N, Joshua AM, Emmett L, Horvath L, Murphy DG, Hsiao E, Balakrishnar B, Lin P, Redfern A, Macdonald W, Ng S, Lee ST, Pattison DA, Nadebaum D, Kirkwood ID, Hofman MS, UpFrontPSMA Study Team

doi: 10.1016/S1470-2045(24)00440-6

ASCO 2024

Genitourinary Cancer

PSMAfore: ¹⁷⁷Lu-PSMA-617 improved time to worsening in HRQoL and pain in taxane-naïve patients with PSMA-positive mCRPC

COMMENTED

Genitourinary CancerNuclear Medicine

Quantitative ⁶⁸Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following ¹⁷⁷Lu-PSMA-617 (VISION Trial)

★ 2 Recommended and commented by Prof. Dr Ken Herrmann, Faculty Member

Radiology

Kuo PH, Morris MJ, Hesterman J, Kendi AT, Rahbar K, Wei XX, Fang B, Adra N, Garje R, Michalski JM, Chi K, de Bono J, Fizazi K, Krause B, Sartor O, Tagawa ST, Ghebremariam S, Brackman M, Wong CC, Catafau AM, Benson T, Armstrong AJ, Herrmann K

doi: 10.1148/radiol.233460

COMMENTED

Genitourinary CancerNuclear Medicine

Renal and Multiorgan Safety of ¹⁷⁷Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy

J Nucl Med

Herrmann K, Rahbar K, Eiber M, Sparks R, Baca N, Krause BJ, Lassmann M, Jentzen W, Tang J, Chicco D, Klein P, Blumenstein L, Basque JR, Kurth J

doi: 10.2967/jnumed.123.265448

ASCO 2024

Genitourinary Cancer

PSMAfore: ¹⁷⁷Lu-PSMA-617 improves clinical outcomes versus ARPI change irrespective of baseline ctDNA fraction or the presence of negative prognostic biomarkers

Related content

[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [(177)Lu]Lu-PSMA-617 in the Phase 3 VISION Trial

Investigating Combination Therapy: The Role of Lutetium-177 PSMA-617 Radioligand Therapy and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer

Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study

PSMAfore: 177Lu-PSMA-617 improved time to worsening in HRQoL and pain in taxane-naïve patients with PSMA-positive mCRPC

Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial)

Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy

PSMAfore: 177Lu-PSMA-617 improves clinical outcomes versus ARPI change irrespective of baseline ctDNA fraction or the presence of negative prognostic biomarkers

[¹⁷⁷Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

Overall survival with [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Sequential [¹⁷⁷Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study

PSMAfore: ¹⁷⁷Lu-PSMA-617 improved time to worsening in HRQoL and pain in taxane-naïve patients with PSMA-positive mCRPC

Quantitative ⁶⁸Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following ¹⁷⁷Lu-PSMA-617 (VISION Trial)

Renal and Multiorgan Safety of ¹⁷⁷Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy

PSMAfore: ¹⁷⁷Lu-PSMA-617 improves clinical outcomes versus ARPI change irrespective of baseline ctDNA fraction or the presence of negative prognostic biomarkers